Answers are grounded in this paper and cite their sources.
Neuromodulation devices, particularly renal sympathetic denervation, offer a promising non-pharmacological strategy for treating resistant hypertension and hypertensive heart disease.
Hypertensive heart disease (HHD) is the leading cause of mortality and morbidity in the United States. Despite the availability of medical therapy it remains a challenge to treat. Autonomic nervous system imbalance resulting in overactivity of the sympathetic nervous system and under activity of the parasympathetic nervous system is integral in the development of hypertension and ultimately the development of HHD. Emerging data suggest that neuromodulation device therapy for treatment of HHD is promising.
No takes yet. Share an insight, caveat, or question.
Todoran et al. (2013) conducted a review in Hypertensive heart disease and resistant hypertension. Neuromodulation device therapy (renal sympathetic denervation, baroreceptor activation therapy, vagal nerve stimulation, spinal cord stimulation) vs. Medical therapy (in reviewed trials) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: